Pulmonary Metastasectomy Following Chemotherapy in Patients with Testicular Tumors: Experience in 52 Patients

Abstract

Background: Surgical resection is an important form of treatment for residual post-chemotherapy pulmonary masses in patients with non-seminomatous germ cell tumors. We analyzed the outcome and prognostic factors after surgery. Methods: Between 1996 and 2001, 52 patients underwent pulmonary resection of thoracic masses following cisplatin-based chemotherapy. These patients' records were subsequently reviewed. Results: The overall 5-year survival rate was 75.8 %. A significantly longer survival was observed using multivariate analysis in patients with normal serum AFP and/or hCG tumor marker levels and after complete surgical resection. In patients with viable malignant tumor cells in the resected specimen and in patients with only necrosis/fibrosis or teratoma, the 5-year survival rates were 49.6 % and 82.8 %, respectively. This difference was only statistically significant in univariate analysis. Conclusions: We conclude that pulmonary resection in metastatic non-seminomatous germ cell tumors is a safe and effective treatment modality. Incomplete resection and elevated tumor marker levels, AFP and/or hCG, were identified as prognosis-related criteria for a poor outcome in multivariate analysis.

Thoracic surgery - non-seminomatous testicular germ cell tumor - prognostic factor

References

• 1 Sharir S, Foster R S, Donohue J P, Jewett M A. What is the appropriate follow-up after treatment?.  Semin Urol Oncol. 1996;  14 45-53
• 2 McGuire M S, Rabbani F, Mohseni H. et al . The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours.  BJU Int. 2003;  91 469-473
• 3 Kulkarni R P, Reynolds K W, Newlands E S. et al . Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis.  Br J Surg. 1991;  78 226-229
• 4 Aprikian A G, Herr H W, Bajorin D F, Bosl G J. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.  Cancer. 1994;  74 1329-1334
• 5 Abel U, Berger J, Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors.  Methods Inf Med. 1984;  23 154-156
• 6 Kaplan E L, Meier P. Nonparametric estimation from incomplete observations.  J Am Stat Assoc. 1958;  53 457-481
• 7 Peto R, Peto J. Asymptomatically efficient rank invariant test procedures.  J R Stat Soc A. 1972;  135 185-206
• 8 Fisher R. Statistical Methods for Research Workers. Edinburgh; Oliver and Boyd 1954
• 9 Cox D. Regression models and life-table (with discussion).  JR Statist Soc, Series B. 1972;  34 187-220
• 10 Liu D, Abolhoda A, Burt M E. et al . Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience.  Ann Thorac Surg. 1998;  66 1709-1714
• 11 Pastorino U, Buyse M, Friedel G. et al . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases.  J Thorac Cardiovasc Surg. 1997;  113 37-49
• 12 Anyanwu E, Krysa S, Buelzebruck H, Vogt-Moykopf I. Pulmonary metastasectomy as secondary treatment for testicular tumors.  Ann Thorac Surg. 1994;  57 1222-1228
• 13 Gels M E, Hoekstra H J, Sleijfer D T. et al . Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified.  Chest. 1997;  112 967-973
• 14 Jauch K W, Koebe H G, Piltz S. et al . Surgery of metastases - can surgery of metastases be radical?.  Zentralbl Chir. 1993;  118 508-515
• 15 Steyerberg E W, Keizer H J, Zwartendijk J. et al . Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.  Br J Cancer. 1993;  68 195-200
• 16 Einhorn L H, Williams S D, Mandelbaum I, Donohue J P. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction.  Cancer. 1981;  48 904-908
• 17 Bajorin D F, Herr H, Motzer R J, Bosl G J. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.  Semin Oncol. 1992;  19 148-158
• 18 Ahmed T, Bosl G J, Hajdu S I. Teratoma with malignant transformation in germ cell tumors in men.  Cancer. 1985;  56 860-863
• 19 Kesler K A, Wilson J L, Cosgrove J A. et al . Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience.  J Thorac Cardiovasc Surg. 2005;  130 408-415
• 20 Cagini L, Nicholson A G, Horwich A. et al . Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors.  Ann Oncol. 1998;  9 1185-1191
• 21 Logothetis C J, Samuels M L, Trindade A, Johnson D E. The growing teratoma syndrome.  Cancer. 1982;  50 1629-1635
• 22 Stephens A W, Gonin R, Hutchins G D, Einhorn L H. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.  J Clin Oncol. 1996;  14 1637-1641
• 23 Kollmannsberger C, Oechsle K, Dohmen B M. et al . Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.  Cancer. 2002;  94 2353-2362
• 24 Steyerberg E W, Keizer H J, Messemer J E. et al . Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.  Cancer. 1997;  79 345-355
• 25 Brenner P C, Herr H W, Morse M J. et al . Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.  J Clin Oncol. 1996;  14 1765-1769
• 26 Horvath L G, McCaughan B C, Stockle M, Boyer M J. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.  Intern Med J. 2002;  32 79-83